ITGAX and neoplasm: Lin et al. (2023) showed that taxifolin downregulates the signature of mouse counterparts of IIT (ITGAL (integrin subunit alpha L)-ITGAX (integrin subunit alpha X)-TMEM119), whose expression (i.e., stromal expressions of ITGAL and ITGAX and tumor expression of TMEM119 in NSCLC) predicts both ICB (immune checkpoint blockade therapy) benefit and mortality risk in NSCLC [140].